Drug profile · INN
dronedarone
MULTAQ
dronedarone (MULTAQ) is a sodium channel alpha subunit blocker. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — dronedarone
- US status
- approved
- Class
- Cardiovascular system (C01)
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
dronedarone (MULTAQ) is a sodium channel alpha subunit blocker. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is dronedarone?
dronedarone (MULTAQ) is a sodium channel alpha subunit blocker. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for dronedarone?
MULTAQ is a marketed brand name for dronedarone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dronedarone?
dronedarone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.